grant
Deciphering HIV-1 Resistance Pathways against Capsid Inhibitors in vitro and in Humanized Mice
Organization UNIVERSITY OF PITTSBURGH AT PITTSBURGHLocation PITTSBURGH, UNITED STATESPosted 10 Feb 2026Deadline 31 Jan 2031
NIHUS FederalResearch GrantFY2026AccelerationAddressAffectAnimal ModelAnimal Models and Related StudiesAnti-viral AgentsAnti-viral TherapyAssayBar CodesBioassayBiological AssayCapsidCell Culture TechniquesCharacteristicsClinicalClinical TrialsConeConserved SequenceCorrelation StudiesDNA mutationDataDevelopmentDoseDrug resistanceDrug resistance pathwayEvolutionFutureGenerationsGeneticGenetic ChangeGenetic defectGenetic mutationGenetics-MutagenesisGrantHIV interventionHIV therapeuticHIV therapyHIV treatmentHIV-1HIV-1 interventionHIV-1 therapeuticHIV-1 therapyHIV-1 treatmentHIV-IHIV1Human Immunodeficiency Virus Type 1Human Immunodeficiency Virus therapyHuman Immunodeficiency Virus treatmentHuman Immunodeficiency Virus-1Human immunodeficiency virus 1In VitroInfectionInterferon Type IInterphase CellInterventionInvestigationKnowledgeLaboratoriesLibrariesLinkMapsModelingMucosaMucosal TissueMucous MembraneMulti-Drug ResistanceMultidrug ResistanceMultiple Drug ResistanceMultiple Drug ResistantMutagenesisMutagenesis Molecular BiologyMutationNon-dividing CellNondividing CellNucleotidesPathway interactionsPhenotypePrEPPreventative strategyPreventionPrevention strategyPrevention trialPreventive strategyProteinsPublic HealthReportingResearchResistanceResistance to Multi-drugResistance to MultidrugResistance to Multiple DrugResistant to Multiple DrugResistant to multi-drugResistant to multidrugResting CellScanningShapesSiteStatistical CorrelationTherapeuticTransmissionValidationVariantVariationViralViral Gene ProductsViral Gene ProteinsViral ProteinsVirusanti-viral compoundanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viralsbarcodebasebasescell culturecell culturescombinatorialcostde novo mutationde novo variantdesigndesigningdevelopmentaldrug resistantdrug resistant pathwayeffective interventioneffective therapyeffective treatmentexperimentexperimental researchexperimental studyexperimentsfitnessgenome mutationhumanized micehumanized mouseimprovedin vivoin vivo Modelinhibitorinsightlarge data setslarge datasetslarge scale datalarge scale data setslarge scale datasetsmodel of animalmouse modelmulti-drug resistantmultidrug resistantmurine modelmutantnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypathwaypre-exposure prophylaxispressurerational designresistance mutationresistance to Drugresistantresistant mutationresistant to Drugtherapeutic targettransmission processtreat HIVtreat Human Immunodeficiency Virustreatment strategyvalidationsviral fitnessviral infectious disease treatmentviral transmissionvirus proteinvirus transmission
Description preview
PROJECT SUMMARY
The HIV-1 capsid, a cone-shaped protein shell, is a promising target for antiviral interventions, with
lenacapavir (LEN), a potent capsid inhibitor, demonstrating efficacy in treatment and prevention. However,
resistance to LEN has been reported in both in vitro and clinical contexts. Our preliminary studies have also
identified…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click